The European Medicines Agency (EMA) has recommended marketing authorizations for two treatments for children with attention-deficit hyperactivity disorder (ADHD). Paxneury, containing guanfacine, has been approved for reducing ADHD symptoms such as hyperactivity and impulsivity. It will be available as prolonged-release tablets. The EMA also recommended Tuzulby, containing methylphenidate hydrochloride, for once-daily dosing to improve attention and behavior throughout the day. Both drugs have been deemed comparable to existing medications in terms of benefits. Potential side effects of Paxneury include hypotension and weight gain, while Tuzulby requires supervision from a specialist. Approval by the European Commission is still pending.
Source link
EMA Endorses Two ADHD Treatments for Children
